Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

To be considered for this study, you would need to have muscle-invasive bladder cancer that is confined to the bladder wall and nearby lymph nodes, without spreading to other parts of the body. You must also be planning to have an operation to remove your bladder (a radical cystectomy). It's important that you haven't had chemotherapy or other immune-boosting cancer treatments for your bladder cancer before, and you should generally be in good health.

There are also some reasons why you might not be able to join. For example, if your cancer has spread widely, or if you've had certain types of radiotherapy to your pelvic area recently. The study also cannot include people who are taking medications that suppress the immune system, or who have certain active infections like Hepatitis or Tuberculosis.

The research team will carry out detailed checks to make sure the study is right and safe for you. They will explain everything clearly, and you'll have plenty of chances to ask questions.

If you decide to take part in this study, you will first undergo a series of assessments to confirm your eligibility. Once enrolled, you will receive treatment. This involves a period of receiving Durvalumab along with Gemcitabine and Cisplatin before your planned surgery. After your surgery to remove the bladder, you will then receive Durvalumab on its own for a period. Throughout the study, you will have regular hospital visits for various tests, scans, and to monitor your health and any side effects. The medical team will explain the exact schedule of visits and treatments, which will span several months, followed by a period of follow-up checks to see how you are doing long-term.